Screen Reader Access







New Drug Discovery Group

New Drug Discovery Group

  1. Coordinators:

    ➤ Dr Sanjay Batra -Medicinal and Process Chemistry

    ➤ Dr Sabyasachi Sanyal -Biochemistry


    Members:

    ➤ Dr Imran Siddiqi -Bio-informatics

    ➤ Dr Manish Chourasia -Pharmaceutics

    ➤ Dr RS Bhatta -Pharmacokinetics

Vision and Goal

➤ Rational design, synthesis and biological screening of synthetic compounds and natural products for discovery of new drug

➤ Repositioning of bioactives

➤ Maintenance of the Repository of Synthetic and pure Natural Compounds for identification of ligands for new biochemical targets

➤ Recruiting compounds from other institutions for assessment of bioactivity

Core Competencies and Activities

➤ Rational design and synthesis of novel organic compounds

➤ Bio-evaluation of synthetic molecules and natural compounds for different disease areas via in vitro and in vivo models

➤ Computational approaches toward identification of new ligands for different targets

➤ Archiving of chemical libraries in the Repository of organic compounds

➤ Maintenance of records of the attributes of each compound with respect to analytical, spectroscopic and biological screening data via the Online Compound Submission and Bioassay Reporting System (CBRS)

➤ Maintenance of SOPs for all bioassays listed and formulation of decision trees for taking the bio-actives to translational mode

➤ Recruiting of organic molecules from other academic institutions for maintenance and bio-evaluation as prelude to discover new bioactives

➤ Analysis of PK parameters of Hits

Drug Discovery At CDRI

➤ Natural Source- Ayurveda/ Ayush

➤ Traditional Source-Inspired Lead

➤ Synthetic Chemistry- Target-Based

➤ Repurposing/Repositioning Of Drug (For Affordable Healthcare)

Repository of Organic Compounds at CSIR-CDRI

Repository of Organic Compounds at CSIR-CDRI

Compound Work flow- Monitoring by the NDDG

Preliminary Bioassay System currently operational at CSIR-CDRI

Cancer

➤ Phenotypic Breast Cancer, Colorectal Cancer
➤ Target-based assays (HDAC, mTOR, proteasome, AKT-kinase)

Parasitic diseases

➤ Antimalarial (P. falciparum, 3D7 and K1 strains)
➤ Antimalarial (Liver stage, secondary screening only)
➤ Antileishmanial (L. donovani, promastigote/ amastigote)
➤ Antifilarial (Micro and Macrofilaricidal)

CNS/CVS disorders

➤ GPCRs Profiling (5HT2C, H3R, KOR, D5, 5-HT6)
➤ Anti-Angiogenesis
➤Anti-Dyslipidemic (Adipogenesis)
➤ Anti-Dyslipidemic (PCSK9)
➤ Anti-Pulmonary hypertension (Tyrosine kinase inhibition)
➤ Anti-Hypertension (ACE Inhibition)
➤ Anti-Parkinson’s Activity (Synuclein aggregation))
➤ Anti-Parkinson’s Activity (C. elegans Synuclein aggregation)
➤ Anti-Inflammatory

Tuberculosis and Microbial Infection

➤Antibacterial (general)
➤ Antibacterial (resistant)
➤Antifungal
➤ Antitubercular

Reproductive Health Research, Diabetes and energy metabolism

➤ Diabetes (Small molecule GLP-1R agonist)
➤ Diabetes Skeletal muscle glucose uptake
➤ Osteoporosis
➤ Spermicidal